سعر اينهيستروك 150 مجم 10 كبسولات 2022

Inhistrok 150 mg (Marcyrl): dabigatran etexilate 150 mg hard capsules, 10 capsules; an oral direct thrombin inhibitor anticoagulant.

• Reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Treatment of deep venous thrombosis and pulmonary embolism after 5-10 days of parenteral anticoagulation, and reduction of the risk of their recurrence.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Prophylaxis of DVT and PE in patients who have undergone hip replacement surgery.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>15%) in adults: gastrointestinal adverse reactions (dyspepsia, gastritis-like symptoms) and bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Active pathological bleeding; history of serious hypersensitivity to dabigatran (e.g. anaphylaxis); mechanical prosthetic heart valve.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: premature discontinuation increases the risk of thrombotic events (consider another anticoagulant if stopped other than for bleeding); spinal or epidural haematoma risk with neuraxial anaesthesia or spinal puncture.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Can cause serious and fatal bleeding; use not recommended in bioprosthetic heart valves; not recommended in triple-positive antiphospholipid syndrome (increased thrombotic events).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• P-gp inducers (e.g. rifampin)Reduce dabigatran exposure; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
• P-gp inhibitors (e.g. dronedarone, systemic ketoconazole)In AF with CrCl 30-50 mL/min consider 75 mg twice daily; avoid with CrCl <30 (AF) or <50 (VTE treatment/prophylaxis).DailyMed (U.S. National Library of Medicine)
• Antiplatelets, NSAIDs, other anticoagulantsIncreased bleeding risk.DailyMed (U.S. National Library of Medicine)

• Limited data in pregnant women are insufficient to inform drug-associated risk; pregnancy confers increased thrombotic risk and anticoagulants increase haemorrhage risk at delivery.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on dabigatran in human milk; breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Dabigatran etexilate: Prodrug converted to dabigatran, a competitive direct inhibitor of free and clot-bound thrombin, preventing fibrin formation and thrombin-induced platelet aggregation.